• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Brisk pace of drug outsourcing deals continues in first half of 2013

Brisk pace of drug outsourcing deals continues in first half of 2013

September 4, 2013
CenterWatch Staff

Crosstree Capital Partners, an investment banking company specializing in advising middle market companies in the drug and device outsourcing industry, has released its second quarter 2013 Drug and Device Outsourcing Industry Monitor.

The brisk pace of mergers and acquisitions, which surged at the end of 2012, continued through the first half of 2013 as both strategic and financial buyers remained active. The development and contract manufacturing segments were the most active, and deal activity in Europe increased considerably.

Private placement activity fell for the second consecutive quarter as a result of a slowdown in European investments.

Revenue- and earnings-based valuations increased across nearly every segment in the industry. The Crosstree Capital Partners Drug and Device Outsourcing Index climbed 4.6% in the second quarter, rising for the third consecutive quarter.

Private placement and M&A deal activity spiked during the fourth quarter of 2012 across all industry segments, according to Crosstree, as the result of a rush to get deals done before tax increases took effect in 2013. As a result, M&A deal volume expectedly dropped across all segments during the first half of 2013, the exception being the development segment. M&A volume was virtually unchanged from the first to the second quarter.

Strategic buyers are expected to continue to look at acquisition prospects for growth, and PE firms to continue to seek platform companies, Crosstree said.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing